Compare PEBK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBK | NKTX |
|---|---|---|
| Founded | 1912 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0M | 132.8M |
| IPO Year | N/A | 2020 |
| Metric | PEBK | NKTX |
|---|---|---|
| Price | $36.89 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 9.7K | ★ 754.6K |
| Earning Date | 02-11-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 3.81 | N/A |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $85,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.06 | ★ N/A |
| Revenue Growth | ★ 6.88 | N/A |
| 52 Week Low | $23.74 | $1.31 |
| 52 Week High | $38.46 | $2.74 |
| Indicator | PEBK | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 72.37 |
| Support Level | $36.05 | $1.93 |
| Resistance Level | $37.60 | $2.19 |
| Average True Range (ATR) | 0.79 | 0.12 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 72.11 | 98.21 |
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.